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A B S T R A C T
The increase of the human population is accompanied by growing numbers of livestock to feed this population,
as well as by an increase of human invasion into natural habitats of wild animals. As a result, both animals and
humans are becoming progressively vulnerable to infections with known (zoonotic) pathogens, but are also
increasingly exposed to novel viruses. Global trade as well as climate changes can contribute to pathogen
transmission, e.g. through import of infected vectors or expansion of habitats for arthropod vectors such as
mosquitoes and midges. Infectious disease outbreaks, especially those by novel viruses, are generally un-
expected, and therefore we should be prepared with tools and abilities for immediate action, including the
identiﬁcation of the causative agent, the evaluation of its pathogenic potential for animals and humans, and the
fast development of diagnostic assays to allow contact tracing and quarantine measures.
HONOURs is a Marie Skłodowska-Curie Actions Innovative Training Network (MSCA-ITN), teaching 15 ta-
lented young researchers to become “preparedness-experts”. HONOURs, initiated in April 2017, involves 11
laboratories from 6 diﬀerent European countries, all at the forefront of novel virus investigations and char-
acterizations. The network includes surveillance experts in both the veterinary and the human health sector, who
have developed and utilize highly sensitive virus discovery techniques, e.g. next generation sequencing based
genomics and universal primers based PCR, to allow identiﬁcation and characterization of novel viruses.
Production of pure viral proteins, providing high-resolution structures, aids in the design of novel, fast and easy-
to-use diagnostics. Organotypic in vitro cell cultures systems (e.g. pseudostratiﬁed human airway epithelia)
provide tools for virus replication, if needed via a reverse genetics platform, and the production of virus stocks
permits inoculation in animal models to examine disease, evaluate candidate vaccines, and fulﬁlment of the
Koch’s postulates. Scientists of the various institutes will provide training in the HONOURs network through
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specialized courses and workshops, combined with challenging research projects. The ﬁnal aim of the network is
to deliver 15 expert scientists, ready to act in case of the emergence of an epidemic.
1. Goals of HONOURs
Infectious diseases have always been a massive burden on the
wellbeing of humans and animals, far beyond the consequences of war
and natural disasters. Infectious outbreaks in animals and humans
emerge unexpectedly, caused by known pathogens or by hitherto un-
known pathogens. History has shown that the spread of unknown an-
imal viruses is the main source of novel viral infections in livestock and
humans. With a novel virus introduction, either in the veterinary or in
the human ﬁeld, it is important to address several essential research
questions, e.g. the geographic location of the introduction and the size
of the epidemic, the disease association, the mortality and morbidity,
the species involved in a transmission chain, and the replication char-
acteristics such as cell- and organ-tropism. Currently there is no com-
prehensive teaching programme for researchers in this area, therefore
the main objective of the HONOURs MSCA-ITN is to train young re-
searchers (Early Stage Researchers: ESRs) on diﬀerent aspects of
emerging viral infections and the threat of zoonotic viruses (Fig. 1). The
ESRs will follow specialized courses supplied by the senior scientists in
HONOURs (Box 1). Each ESR will also have an individual research topic
leading to a thesis defence and the awarding of a PhD degree (Box 2).
1.1. Recognizing an introduction
In case of emerging or re-emerging epidemics, the recognition of an
introduction is of utmost importance. In general, this depends on syn-
drome surveillance and diﬀerential diagnostics, operational in most
European countries, with local and national syndrome notiﬁcation
protocols. However, infections causing milder disease, or less re-
cognizable disease symptoms, remain below the surface and are likely
missed when only syndrome surveillance is operational. Recognition of
these introductions requires not only the close observation of disease
symptoms, but also careful evaluation of unexpected negative results in
diagnostic tests for known pathogens. There are possibilities within
HONOURs to recognize also these milder or hidden outbreaks, as most
institutes in HONOURs perform infectious disease diagnostics, and have
access to data or information on diagnostic samples from patients with
clinical symptoms of unknown etiology. For exactly this reason an
Outbreak Antenna team has been formed within HONOURs, as a hands-
on platform for the ESRs to develop, explore, and test their ideas, using
the diagnostic results and data available at their institute as their
playing ground.
1.2. Identiﬁcation of an introduction
With standard diagnostics, like cell culture, serology, or PCR, it is
diﬃcult to identify unexpected or novel viruses. Therefore, generic de-
tection and identiﬁcation assays building on the latest developments in
sequencing and sequence analysis are needed to identify all potentially
viral sequences. HONOURs has multiple beneﬁciaries on-board that are
at the forefront of novel pathogen detection and characterization.
Unbiased sequencing techniques have been developed by three members
in HONOURs: 1. Direct next-generation sequencing (Direct-NGS)
(Hoﬀmann et al., 2012), 2. VIDISCA-NGS (de Vries et al., 2011), and 3.
The NetoVIR method (Conceição-Neto et al., 2015). These three techni-
ques complement each other. The VIDISCA and NetoVIR techniques in-
clude an ampliﬁcation step during library preparation and are thus more
suitable for virus detection in samples containing low concentrations of
nucleic acids, like serum, plasma, cerebrospinal ﬂuid, respiratory and
anal swabs. Direct-NGS is a shotgun sequencing approach lacking an
ampliﬁcation step, thereby reducing the bias of the sample library pre-
paration step. Moreover, the direct-NGS is capable of virus detection in
complex materials like solid tissues. Another diﬀerence among the
techniques is how DNA fragmentation is performed. VIDISCA is based on
restriction enzyme digestion at ﬁxed positions, having the advantage that
repeated detection of fragments provides the certainty of presence in a
Fig. 1. Scheme of the research and training
topics in HONOURs. In case of a novel in-
troduction of a virus into the human or animal
ﬁeld, the ﬁrst step in HONOURs is recognition
of the introduction followed by identiﬁcation
of the virus, communication to the relevant
stakeholders (awareness), generating fast and
easy to use diagnostics, culturing of the virus,
setting up of an animal model system and
vaccine development.
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clinical sample. The random shearing-based methods (NetoVIR and Di-
rect-NGS) have the beneﬁt of producing sequence reads that can form
contigs via overlapping reads. Contigs are generally larger than single
sequence reads and thus more suitable for phylogeny and identity
searches. Not only metagenomics techniques, but also sensitive generic
PCRs (Drexler et al., 2015) and microarrays (Abendroth et al., 2017)
provide powerful tools to identify new members within known virus
families, and both techniques are part of HONOURs.
Box 1
Research Work Packages and Network-Wide Training Events in HONOURs.
• WP2-Outbreak Antenna: Infectious diseases; Outbreak Antenna Meeting. Sites involved: FLI, EDI-IVI, MSD-AH, AMC, KU Leuven, UBern,
Spiez, Charité (see legend of Fig. 2 for institute abbreviations).
• WP3-Pathogen Discovery: VIDISCA-NGS; Random priming-NGS (NetoVIR); Direct-NGS; Metagenomics and microarrays for virus detection;
High throughput nested RT-PCR and degenerative oligonucleotide design; High throughput analysis of ticks and mosquitoes by pan-virus
family/ real-time RT-PCR. Sites involved: FLI, AMC, KU Leuven, Spiez, Charité, UBern, BPRC.
• WP4-Virus Culture and Animal Models: Nonhuman primates in biomedical research; Reverse genetics; Virus-host interactions on airway
epithelia; BSL3/3+ trans-boundary animal course; Commercial vaccine development. Sites involved: AMC, FLI, BPRC, MSD-AH, EDI-IVI.
• WP5-Advanced Diagnostics: Novel diagnostics; Protein production and serology; Flavivirus serology; High throughput nested RT-PCR and
degenerative oligonucleotide design. Sites involved: Charité, ULeeds, INGENASA, UBern.
• WP6-Awareness: Infectious diseases; Media training. Sites involved: AMC, KU Leuven, FLI, Charité.
Box 2
ESR Individual Research Projects.
(1)
(1) Unknown viruses in animal/human diseases (AMC). Diseases like pathogen negative-diarrhoea, -respiratory tract infections, and
AIDS-related chronic immune activation, may be inﬂuenced by unexpected or unknown virus infections. Investigation by VIDISCA-
NGS and antibody capture-VIDISCA, will reveal the inﬂuence of viruses and vectors in disease.
(2) Human gut viral metagenome in the ﬁrst years of life (KU Leuven). Reveal whether the gut virome dynamics of infants is inﬂuenced
by factors, such as hygienic and socio-economic environments, antibiotics, disease, diet, and vaccination.
(3) Optimized cascaded next-generation virus detection and molecular characterization (FLI). Analyse and characterize all novel
pathogens via a one-ﬁts-all platform. Direct metagenomics platforms and assays will be further optimized through best selection of
samples, sample preparation, and data analysis.
(4) Prevalence and disease association of newly detected microorganisms (Charité). Genomic characterization and evolutionary re-
constructions of novel viruses can elucidate potential viral reservoirs. Zoonotic origins of new viruses will be investigated by phy-
logenetic inference, ancestral state reconstructions and hypothesis testing.
(5) Isolation and molecular analysis of zoonotic emerging respiratory viruses (EDI-IVI). Genetically modiﬁed primary airway epi-
thelial cell cultures have been established that are transduced with lentivirus constructs to express speciﬁc genes of interest. The virus-
induced host responses on the (transduced) pseudo-stratiﬁed primary airway epithelia cell cultures will be investigated.
(6) Replication of novel viruses in epithelial cells (AMC). Virus discovery using organotypic in vitro cultures. Replication will be in-
vestigated via single cell transcript sequencing and aspeciﬁc infection-staining techniques.
(7) Establishment of a reverse genetics platform for emerging viruses (EDI-IVI). Emerging viruses are often diﬃcult to isolate and
sometimes only the genomic sequence is available. Cloning of full-length cDNA from sequencing information combined with the
expertise to rescue recombinant viruses will bypass the virus isolation step.
(8) Pathogenic potential of novel ﬂaviviruses (BPRC). The early pathological events following Usutu and Zika virus infection will be
investigated by infection of cell lines, and primary cells from a natural host: nonhuman primates.
(9) New approaches to conﬁrm involvement in disease (MSD-AH). Identify novel viral pathogens, design 2D and 3D culture platforms,
conﬁrm involvement in disease and work towards a vaccine solution.
(10) Development of diagnostic methods for newly discovered viruses (INGENASA). Detection of zoonotic viruses of the Bunyvirales,
such as Crimean-Congo hemorrhagic fever virus and Rift Valley fever virus. Multiplex serology tests will be developed for the dif-
ferential diagnosis between these two and other related viruses.
(11) Viral nucleocapsid proteins, their structure and novel diagnostic assays (ULeeds). Elucidate molecular structures of viral nu-
cleoproteins and nucleocapsid complexes of bunyaviruses and paramyxoviruses.
(12) In vitro and in vivo characterization of viral pathogens (FLI). Novel viruses will be cultured on suitable cell cultures from the
collection at the FLI (> 1250 diﬀerent cell lines). An animal model will serve as an alternative approach to promote virus replication,
collect polyclonal antisera, and achieve a ﬁrst challenge model.
(13) Detection and sequencing methods for the identiﬁcation of new and emerging viruses (UBern). Evaluate sample preparation and
sequencing protocols for adenovirus-containing clinical samples (model system) supplemented with virus family wide PCR assays to
identify novel virus family members in ticks, mosquitos, and rodents.
(14) Development of impedimetric sensors for emerging arena- and bunyaviruses (ULeeds). Generate impedance-based detection
assays by protein expression/puriﬁcation, antibody and Aﬃmer production, biosensor fabrication and testing. The structure of the
viral antigen used in the biosensor device will be determined by electron microscopy.
(15) Full genomic sequencing of viral pathogens with large genomes (KU Leuven). Optimising ultra-long read sequencing protocols
(e.g. MinION™) to investigate intra-host and inter-host genetic diversity of human cytomegalovirus and relate to the prognosis and
treatment of a patient.
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1.3. Fast detection and association with disease
Once a novel or newly emerging virus is identiﬁed and involvement
in a disease is suspected, establishment of the association with disease is
vital. To study this association, sensitive and speciﬁc detection assays
are needed, not only for the pathogen, but also for the antibody re-
sponse elicited by the viral infection. Within HONOURs several in-
stitutes are involved that develop sensitive and speciﬁc detection assays
for the virus and/or antibodies to the virus. The laboratories provide
sensitive, high throughput, real time PCR assays and serological tests
(Oechslin et al., 2017; Corman et al., 2016; Sastre et al., 2016). Fur-
thermore, assay development within HONOURs also includes impedi-
metric sensoring, which oﬀers rapid and highly sensitive detection of
virus particles, viral proteins and also anti-viral antibodies, in-
dependently of PCR or immunostaining techniques (Ahmed et al.,
2013). The puriﬁed viral proteins needed for the diagnostic assays will
also be used for both Titan Krios cryo-EM imaging and crystallization
trials with high-resolution structures as a result. These structures pro-
vide information regarding the function of the proteins in the viral
replication cycle, the evolutionary relatedness when compared to other
known structures, and a rationale of exposed antigenic sites, important
for monoclonal antibody production (Carter et al., 2012; Surtees et al.,
2015).
1.4. Fulﬁlling Koch’s postulates
Apart from the ﬁrst detection of a novel viral introduction and es-
tablishing the association with disease, it is important to fulﬁl the
Koch’s postulates as part of the virus characterization steps (Loeﬄer,
1884):
• The microorganism must be found in abundance in all organisms
suﬀering from the disease, but should not be found in healthy
organisms.
• The microorganism must be isolated from a diseased organism and
grown in pure culture.
• The cultured microorganism should cause disease when introduced
into a healthy organism.
• The microorganism must be re-isolated from the inoculated, dis-
eased experimental host and identiﬁed as being identical to the
original speciﬁc causative agent.
A necessity for the fulﬁlment of the postulates is a virus culture
stage to acquire pure virus stocks for inoculation in an animal model
system. HONOURs will focus on novel strategies for virus culture using
primary cells. Airway epithelia is the main portal of respiratory virus
entry, thus primary epithelial cells will be the ﬁrst choice to be used in
virus culture. The epithelial cells will be stimulated to diﬀerentiate,
providing an elegant system that mimics the site of virus entry (e.g. the
diﬀerentiated epithelia of the respiratory tract) (Jónsdóttir and
Dijkman, 2016; Kindler et al., 2013).
The target cells will not only be cultured from humans but also from
various animals e.g. pig, monkey, birds, bats. These advanced virus
culture systems may allow propagation of viruses that cannot be cul-
tured in conventional cell line-based culture systems (Pyrc et al., 2010).
In case of virus replication, the virus harvests are to be used in animal
models with the aim to prove involvement in disease by fulﬁlling the
Koch’s postulates.
Isolation of emerging viruses in cell culture can be diﬃcult due to
limited quality, quantity or availability of sample material. However,
often there is a genomic sequence available. In such cases it is possible
to generate (c)DNA clones of a novel virus that can be introduced in a
host cell via transfection. In combination with a rescue system – e.g. the
diﬀerentiated epithelial system described above - the infectious virus
might be obtained and subsequently used for inoculation in an animal
model. If neither conventional cell lines nor any primary cell culture
Fig. 2. Countries (blue) and institutes participating in HONOURs. The HONOURs consortium consists of 11 laboratories, from the following universities/companies/
institutes: Academic Medical Center, University of Amsterdam (AMC); Rega Institute for Medical Research of the Katholieke Universiteit Leuven (KU Leuven);
Institute of Virology at the Charité - Universitätsmedizin Berlin (Charité); Institute for Infectious Diseases, University of Bern (UBern); School of Molecular and
Cellular Biology at the University of Leeds (ULeeds); MSD Animal Health (MSD-AH); Inmunología y Genética Aplicada SA (INGENASA); Friedrich-Loeﬄer-Institut
(FLI); Eidgenössisches Departement des Inneren, Institute of Virology and Immunology (EDI-IVI); Biomedical Primate Research Centre (BPRC); and Labor Spiez
(Spiez). The map was generated using QGIS (www.qgis.org) and open source data from Natural Earth (http://www.naturalearthdata.com) (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.).
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system is available for virus propagation, infectious virus can even di-
rectly be obtained following transfection of the genetic material. Once
an animal model system is established, the disease and the viral pa-
thogenicity can be studied, followed by studies on vaccine candidates.
1.5. Fifteen experts on host switching pathogens, infectious outbreaks and
zoonosis
Apart from receiving education on all abovementioned subjects,
each ESR will have an individual research project (see Box 2). The re-
search topics addressed are based on the expertise of the ESR-em-
ploying institute or company (see Fig. 2). The wealth of the specialized
trainings and the challenging research projects resulting in a PhD de-
gree is the strength of HONOURs, the royal jelly preparing 15 promising
scientists for the future.
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